MYC oncogene found to drive DNA repair in tumours, blunting chemotherapy

Researchers have identified an unexpected role for MYC — one of the most studied oncoproteins in cancer biology — in helping tumour cells survive genotoxic treatment. MYC is already well characterised as a transcription factor that drives uncontrolled cell proliferation; the new work, summarised by ScienceDaily on 17 May 2026, shows that MYC also localises directly to sites of DNA double-strand breaks and recruits the cellular repair machinery there.

The finding offers a potential explanation for a longstanding clinical observation: tumours with high MYC expression frequently show reduced responses to chemotherapy and radiotherapy, both of which work in part by inducing DNA damage that triggers cell death. If MYC accelerates the resolution of that damage, it may effectively shorten the window in which treatment is lethal to cancer cells.

The primary research source was not identified by name in the available press summary, and the originating journal and institution are not yet specified in publicly available reporting. Once a peer-reviewed publication is identified, Genetic Current will update this cluster with full attribution.

For researchers working on transcription-factor biology, oncogene function, or treatment resistance mechanisms, the study raises the possibility that MYC inhibition — an active area of drug development — could have a dual benefit: reducing proliferative signalling and simultaneously sensitising tumours to DNA-damaging agents. No clinical application is described in the current reporting; the work appears to be at the mechanistic research stage.